Yes. Each customer institution can delegate members to join the disease review meetings, hosted by Dana-Farber Cancer Institute, and participate in discussions around new and improved pathways. This collaborative process between Dana-Farber oncologists and your hospital’s oncologists promotes opinion diversity and pathways updates being developed with your institution and expertise in mind.